Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
24-26 June, 2025
Not Confirmed
Not Confirmed
09-11 June, 2025
Annual Outsourcing in ...Annual Outsourcing in CT
Not Confirmed
Not Confirmed
10-11 June, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
24-26 June, 2025
Industry Trade Show
Not Confirmed
09-11 June, 2025
Annual Outsourcing in ...Annual Outsourcing in CT
Industry Trade Show
Not Confirmed
10-11 June, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/excipient-market-overview-roquette-announces-restructuring-post-iff-pharma-buyout-who-fda-advance-regulatory-frameworks
19 Mar 2025
// FIERCE PHARMA
https://www.fiercepharma.com/pharma/astrazeneca-signs-135b-alteogen-deal-subcutaneous-cancer-drugs-despite-merck-halozyme-patent
09 Nov 2024
// PHARMAPHORUM
https://pharmaphorum.com/news/daiichi-sankyo-partners-alteogen-subcutaneous-enhertu
05 Sep 2023
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/alteogens-tergase-novel-recombinant-human-hyaluronidase-injection-shows-excellent-immunogenicity-profile-301916724.html
22 Feb 2023
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/altos-biologics-a-subsidiary-of-alteogen-completed-patient-enrollment-in-global-phase-3-clinical-trial-of-eylea-biosimilar-in-neovascular-age-related-macular-degeneration-301752666.html
03 Jan 2023
// BUSINESSWIRE
08 Mar 2021
// BUSINESSWIRE
https://www.businesswire.com/news/home/20210308005025/en/Alteogen-Announces-Completion-of-Phase-1-Clinical-Trial-of-Aflibercept-Biosimilar-in-Wet-AMD-Patients#:~:text=DAEJEON%2C%20South%20Korea%2D%2D(BUSINESS,Biosimilar%20(ALT%2DL9).&text=Eylea%C2%AE%20is%20a%20drug,along%20with%20cataracts%20and%20glaucoma.
ABOUT THIS PAGE